Epoch 40: Emerging Therapeutic Modalities Expand the Universe of Druggable Targets

Small Molecules, Large Molecules, and Beyond

Welcome to the 45 NEW Biotech Innovators who have joined us this month! If you haven’t subscribed, join the 1,341 researchers, investors, operators, academics, clinicians and entrepreneurs by subscribing here:

Hello Avatar! Welcome back for another week of biotech analysis. This week we will be going into the detail on modalities for therapeutic development.  Traditionally most drugs have either been small molecules (pills) or large molecules (antibodies).   While those modalities will no doubt continue to have their place go-forward, today we see much more diversity in terms of modality.  Tomorrow’s modalities will enable access to target space which was previously considered undruggable.  We will take you through this evolution, highlight which modalities will be most appropriate for each disease area and shed light on time to maturity.

We are now operating under a hybrid subscription model where the Sunday update has moved under the paywall - a BIG THANK YOU to those that have joined. The Thursday market update will continue to remain free. The more forward looking content, the insider insights, and market data you need to really assess what is happening in the world of biotech will shift to Sundays.  

Monday’s equity research will be a deep dive into Atara Biotherpeutics ($ATRA) and their November Phase 2 data readout from ATA188 in MS (EMBOLD Study). Options pricing suggests a ~100% move, so should be one to watch!

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients.  Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.

Enough shilling for the day, lots to cover this week, let's get started!

2 DECADES OF MODALITY HISTORY

This week we are going to dive into one of our favorite topics - therapeutic modalities. What do we mean by this exactly?  One can think of the modality as the delivery formulation.  Delivery is such a hot topic these days, particularly in the area of genetic medicine that we thought it would be an interesting run through the history as well as future directions for Therapeutics modality development.

For those interested in therapeutic modality development, we refer you to other past write up where we deep dived into:

ADCs: Epoch 19: ANTIBODY DRUG CONJUGATES (ADCs)

Gene Editing: Week 1 - The Future is Today with Gene Editing / Writing?

Targeted Protein Degraders: Week 52 - Drugging the UnDruggable

Targeted Protein Degraders:Epoch 18: TARGETED PROTEIN DEGRADATION

Multi-Functional Antibodies: Week 51: Promiscuous Drugs - A Good Thing!